For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Shionogi Licenses NF-κB Decoy Oligo from AnGes MG
January 10, 2011
- Pharmarise to Increase Sales in Home Healthcare Business
January 10, 2011
- National Medical Expenditure Up 2% to ¥34,808.4 Bil.
January 10, 2011
- BMS Licenses Festinavir from Oncolys
January 10, 2011
- Signatures from 2.7 Mil. People Presented Demanding Expansion of Vaccination Programs
January 10, 2011
- Bristol-Myers, Otsuka Starts Copromoting Sprycel in Japan
January 10, 2011
- JRIA Hosts Seminar for Promoting Benefits of RI Treatment
January 10, 2011
- Eisai to Markets Analgesic Poultice in China
January 10, 2011
- FDA Warns Yuki Gosei Kogyo against CGMP Violations
January 10, 2011
- Nippon Kayaku to Lead Antibody Biosimilar Market in Japan: Nomura Securities Report
January 3, 2011
- Eisai Applies for Marketing Authorization for Embolic Beads
January 3, 2011
- Sanofi-aventis to Tie Up with Merck Serono in Oncology
January 3, 2011
- Taiyo Holds Meetings with Clients on GMP Compliance Measures
January 3, 2011
- ARBs Effective for Improving Albuminuria: DSP survey
January 3, 2011
- DSP Completes Merger of Chinese Subsidiaries
January 3, 2011
- US Generics Market to Outgrow New Drugs Market: IGPA Annual Conference
January 3, 2011
- Pfizer Applies for Solu-Medrol Based on Data from the Public Domain
January 3, 2011
- Shionogi, Wakamoto to Copromote Non-prescription Oral Care Products
January 3, 2011
- Apollo Medical to Expand Overseas Training Program for Its Employees
January 3, 2011
- FDA Recommends Withdrawal of Approval for Breast Cancer for Avastin
January 3, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…